Top Markets
Coin of the day
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
주식 순위 #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
주가
$0.003084
시가총액
$434.03K
변동 (1일)
-7.14%
변동 (1년)
-89.24%
국가
BE
거래 Oxurion N.V. (OXUR)

카테고리

Oxurion N.V. (OXUR)의 EPS
2026 기준 EPS TTM: 0
Oxurion N.V.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Oxurion N.V.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS